Notice of AGM

    


Entelos Inc.



                                  ENTELOS, Inc.

                          ("Entelos" or "the Company")

               2007 ANNUAL REPORT AND ACCOUNTS & AGM NOTIFICATION

Entelos, Inc. (LSE:ENTL), gives notice that copies of the 2007 Annual Report and
Accounts and the Notice of Annual General Meeting have been sent to
shareholders. These documents are also available on the Investor Relations page
of the Company's web site at
http://www.entelos.com/investors.php?ID=financialresults

Further copies of the 2007 Annual Report and Accounts are available from the
Company Secretary, Alan Blazei, CFO, Entelos, Inc., 110 Marsh Drive, Foster
City, CA 94404, USA.

Entelos also announces that its Annual General Meeting ("AGM") will be held on
Tuesday, 20 May 2008 at 8:30 am local time. The meeting will be held at the
offices of Travers Smith, located at 10 Snow Hill, London EC1A 2AL, UK.

For Further Information:

Entelos, Inc.
Alan Blazei, CFO                                          Tel: +1 650 572 5400
Jill Fujisaki, VP Investor Relations
KBC Peel Hunt, Ltd (Nominated Advisor and Broker)
Capel Irwin/David Anderson                                Tel +44 (0) 20 4718 8900
Buchanan Communications
Lisa Baderoon / Mary-Jane Johnson                         Tel +44 (0) 20 7466 5000

Notes for Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines and
health-care related consumer products are discovered, developed, and utilized.
The Company leverages its proprietary in silico disease models, "virtual
populations", and toxicology reference systems to develop safer and more
effective drugs for pharmaceutical R&D and to help improve the quality of
health-care related consumer products. Entelos provides customized technology
and research services to global pharmaceutical, health-care, and consumer
products companies in arthritis, cardiovascular diseases, asthma, obesity,
diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization,
and personal care products. The Company is also developing a model in oncology
and is collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys Ltd.

Entelos Regs (LSE:ENTL)
過去株価チャート
から 5 2024 まで 6 2024